{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:57:49Z","timestamp":1791572269460,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006733","name":"Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsat.2019.06.011","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T12:09:43Z","timestamp":1561723783000},"page":"72-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Court personnel attitudes towards medication-assisted treatment: A state-wide survey"],"prefix":"10.1016","volume":"104","author":[{"given":"Barbara","family":"Andraka-Christou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2019.06.011_bb0005","author":"Adult Drug Court Best Practice Standards"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.011_bb0010","first-page":"189","article-title":"What is treatment for opioid addiction in problem-solving courts? A study of 20 Indiana drug & veterans courts","volume":"13","author":"Andraka-Christou","year":"2017","journal-title":"Stanford J. Civil Rights & Civil Liberties"},{"key":"10.1016\/j.jsat.2019.06.011_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2017.11.021","article-title":"A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices","volume":"54","author":"Andraka-Christou","year":"2018","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.011_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2007.11.019","article-title":"Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention","author":"Bruce","year":"2008","journal-title":"International Journal of Drug Policy"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.011_bb0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.2008.976","article-title":"Treating drug abuse and addiction in the criminal justice system: Improving public health and safety","volume":"301","author":"Chandler","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2019.06.011_bb0030","article-title":"White house takes important first step toward fixing broken drug court system","author":"Davies","year":"2015","journal-title":"Drug Policy Alliance"},{"issue":"11","key":"10.1016\/j.jsat.2019.06.011_bb0035","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jama.2017.9308","article-title":"Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000-2015","volume":"318","author":"Dowell","year":"2017","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.011_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08897077.2011.611460","article-title":"Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): Availability, barriers, and intentions","volume":"33","author":"Friedmann","year":"2012","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2019.06.011_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cct.2016.12.015","article-title":"Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment","volume":"53","author":"Gordon","year":"2017","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.jsat.2019.06.011_bb0050","series-title":"To grow market share, a drugmaker pitches its product to judges","author":"Harper","year":"2017"},{"key":"10.1016\/j.jsat.2019.06.011_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/j.1360-0443.2011.03676.x","article-title":"The effectiveness of opioid maintenance treatment in prison settings: A systematic review","author":"Hedrich","year":"2012","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.011_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S2045796011000552","article-title":"Gender differences in public beliefs and attitudes about mental disorder in western countries: A systematic review of population studies","volume":"21","author":"Holzinger","year":"2012","journal-title":"Epidemiology and Psychiatric Sciences"},{"key":"10.1016\/j.jsat.2019.06.011_bb0065","doi-asserted-by":"crossref","DOI":"10.1080\/08897077.2015.1010031","article-title":"Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence","author":"Jackson","year":"2015","journal-title":"Substance Abuse"},{"issue":"7","key":"10.1016\/j.jsat.2019.06.011_bb0070","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.011_bb0075","first-page":"7","article-title":"Reversed items in Likert scales: Flitering out invalid responders","volume":"25","author":"J\u00f3zsa","year":"2017","journal-title":"Journal of Psychological and Educational Research"},{"key":"10.1016\/j.jsat.2019.06.011_bb0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drugpo.2017.05.039","article-title":"Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone","volume":"46","author":"Kelty","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.011_bb0085","first-page":"1","article-title":"Long-acting injectable naltrexone for the management of patients with opioid dependence","volume":"5","author":"Kjome","year":"2011","journal-title":"Substance Abuse: Research and Treatment"},{"issue":"12","key":"10.1016\/j.jsat.2019.06.011_bb0090","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Affairs"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.011_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"13","key":"10.1016\/j.jsat.2019.06.011_bb0100","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2019.06.011_bb0105","doi-asserted-by":"crossref","unstructured":"Lee, J. D., Nunes, E. V, Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., \u2026 Rotrosen, J. (2017). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. The Lancet. doi:https:\/\/doi.org\/10.1016\/S0140-6736(17)32812-X.","DOI":"10.1016\/S0140-6736(17)32812-X"},{"issue":"10118","key":"10.1016\/j.jsat.2019.06.011_bb0110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jsat.2019.06.011_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2014.08.015","article-title":"Medication-assisted treatment for opioid use disorders in correctional settings: An ethics review","author":"Ludwig","year":"2014","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.011_bb0120","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.06.011_bb0125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jsat.2012.10.004","article-title":"Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes","volume":"44","author":"Matusow","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.011_bb0130","author":"Medications for Opioid Use Disorder TIP 63 Treatment Improvement Protocol For Healthcare and Addiction Professionals, Policymakers, Patients, and Families"},{"key":"10.1016\/j.jsat.2019.06.011_bb0135","author":"Medications to treat opioid use disorder"},{"key":"10.1016\/j.jsat.2019.06.011_bb0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.011_bb0145","author":"National Institutes of Health (NIH)"},{"key":"10.1016\/j.jsat.2019.06.011_bb0150","author":"Mehta"},{"issue":"9","key":"10.1016\/j.jsat.2019.06.011_bb0155","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2017.0001","article-title":"Opioid agonist treatment for patients with dependence on prescription opioids","volume":"317","author":"Nielsen","year":"2017","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.011_bb0160","article-title":"Medication-assisted treatment for opioid use disorders in drug courts ensuring the safe, effective, and responsible use of addiction medications for drug court participants","volume":"11","author":"Nordstrom","year":"2016","journal-title":"Drug Court Practitioner Fact Sheet"},{"key":"10.1016\/j.jsat.2019.06.011_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2009.06.015","article-title":"Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a Nationwide survey","author":"Nunn","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.06.011_bb0170","unstructured":"Pariente, B. (n.d.). The Opioid Crisis and How Family Court Judges Can Respond. Retrieved from https:\/\/www.flcourts.org\/Resources-Services\/Court-Improvement\/Problem-Solving-Courts\/The-Opioid-Crisis."},{"issue":"4","key":"10.1016\/j.jsat.2019.06.011_bb0175","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: Findings from starting treatment with agonist replacement therapies (START)","volume":"74","author":"Potter","year":"2013","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10.1016\/j.jsat.2019.06.011_bb0180","unstructured":"Pretrial Diversion. (n.d.). Retrieved from http:\/\/www.ncsl.org\/research\/civil-and-criminal-justice\/pretrial-diversion.aspx."},{"key":"10.1016\/j.jsat.2019.06.011_bb0185","series-title":"Results from the 2012 National Survey on drug use and health: Summary of National Findings","year":"2013"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.011_bb0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jurban\/jti072","article-title":"Attitudes and practices regarding the use of methadone in US state and federal prisons","volume":"82","author":"Rich","year":"2005","journal-title":"Journal of Urban Health"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.011_bb0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Annals of Family Medicine"},{"key":"10.1016\/j.jsat.2019.06.011_bb0200","author":"Senator Harris Launches Investigation into Pharmaceutical Manufacturer Alkermes Regarding Opioid Addiction Treatment Manipulation"},{"key":"10.1016\/j.jsat.2019.06.011_bb0205","first-page":"27","article-title":"Pharmacotherapy for opioid dependence in jails and prisons: Research review update and future directions","volume":"7","author":"Sharma","year":"2016","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/j.jsat.2019.06.011_bb0210","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1016\/j.jsat.2019.06.011_bb0215","doi-asserted-by":"crossref","unstructured":"Sullivan, M. A., Bisaga, A., Pavlicova, M., Carpenter, K. M., Choi, C. J., Mishlen, K., \u2026 Nunes, E. V. (2018). A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. American Journal of Psychiatry, appi.ajp.2018.1. doi:https:\/\/doi.org\/10.1176\/appi.ajp.2018.17070732.","DOI":"10.1176\/appi.ajp.2018.17070732"},{"issue":"12","key":"10.1016\/j.jsat.2019.06.011_bb0220","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2019.06.011_bb0225","series-title":"1999 meeting of the American Statistical Association","article-title":"Cognitive interviewing: A \u201chow to\u201d guide","author":"Willis","year":"1999"},{"key":"10.1016\/j.jsat.2019.06.011_bb0230","series-title":"Thousand Oaks","article-title":"Cognitive interviewing: A tool for improving questionnaire design","author":"Willis","year":"2005"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054721830624X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054721830624X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:50:09Z","timestamp":1760039409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074054721830624X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":46,"alternative-id":["S074054721830624X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.011","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Court personnel attitudes towards medication-assisted treatment: A state-wide survey","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}